Compare Biogen Inc (BIIB) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $32.61. Which is the better fit depends on your goals.
| BIIB | GSG | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $216.63 | $34.77 |
52-Week Low | $128.93 | $22.06 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
GSG, the iShares S&P GSCI Commodity-Indexed Trust ETF, trades at $32.62, up 0.93% on the day, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The ETF's performance is heavily tied to energy commodities, which drove strong gains in H1 2026, though recent analyst sentiment has turned cautious due to sector volatility. Key support is at $31, with resistance at $32.
The outlook for GSG hinges on commodity market dynamics, particularly energy prices, offering exposure to broad commodities but facing risks from geopolitical tensions and volatility. Investor caution is warranted as analysts highlight increased risks near current price levels, with a recent downgrade to Hold reflecting concerns over sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
